Protagonist Therapeutics' stock has declined recently, but its ROE of 32% is promising, reflecting efficient capital utilization and profitability. The company's net income growth of 25% over the past five years is higher than the industry average of 19%.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing